Literature DB >> 28988898

Elevated Aqueous Cytokine Levels in Eyes With Ocular Surface Diseases.

Naohiko Aketa1, Takefumi Yamaguchi2, Teru Asato1, Yukari Yagi-Yaguchi1, Terumasa Suzuki3, Kazunari Higa3, Toshihide Kurihara4, Yoshiyuki Satake3, Kazuo Tsubota4, Jun Shimazaki3.   

Abstract

PURPOSE: To evaluate cytokine and protein levels in the aqueous humor (AqH) of eyes with ocular surface diseases.
DESIGN: Prospective consecutive case series.
METHODS: This study includes 14 patients (aged 62.4 ± 13.7 years) with chronic-phase ocular surface diseases (4 with ocular cicatricial pemphigoid, 5 with chemical burns, 2 with a thermal burn, 2 with Stevens-Johnson syndrome, and 1 with exposure keratitis), 14 matched patients without ocular surface disease (controls with corneal scar), and 30 patients who underwent cataract surgery (healthy controls). AqH samples were collected at the beginning of surgery. AqH levels of cytokines (interleukin [IL]-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, monocyte chemotactic protein [MCP]-1, interferon [IFN]-α, IFN-γ, macrophage inflammatory protein [MIP]-1α, MIP-1β, P-selectin, E-selectin, soluble-intercellular adhesion molecule [s-ICAM]-1, tumor necrosis factor [TNF]-α, granulocyte-macrophage colony-stimulating factor [GM-CSF], IFN-γ-induced protein [IP]-10) were measured using multiplex beads immunoassays.
RESULTS: The levels of IL-6, IL-10, IL-17A, GM-CSF, E-selectin, P-selectin, and s-ICAM in AqH were significantly elevated in eyes with ocular surface diseases (in pg/mL: 1696 ± 804, 4.0 ± 1.0, 24.3 ± 9.8, 26.0 ± 18.3, 5150 ± 1232, 13122 ± 7219, and 7914 ± 2813, respectively), compared to healthy controls (IL-6: 6.36 ± 0.94, P = .001; IL-10: 1.68 ± 0.04, P = .0006; IL-17A: 3.7 ± 0.2, P = .008; GM-CSF: 2.7 ± 0.3, P = .007; E-selectin: 2093 ± 37, P = .0001; P-selectin: 3658 ± 137, P = .0001; sICAM-1: 1397 ± 119, P = .008). The levels of IL-6, IL-17A, E-selectin, and P-selectin in AqH were significantly higher in eyes with ocular surface diseases compared to those with corneal scar (IL-6: 44.1 ± 15.0, P = .0077; IL-17A: 4.1 ± 0.7, P = .034; E-selectin: 2439 ± 302, P = .039; and P-selectin: 5673 ± 1553, P = .017).
CONCLUSIONS: Multiple AqH cytokine levels were elevated in chronic ocular surface diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28988898     DOI: 10.1016/j.ajo.2017.09.029

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

Review 2.  Monitoring Neurodegeneration in Glaucoma: Therapeutic Implications.

Authors:  Norimitsu Ban; Carla J Siegfried; Rajendra S Apte
Journal:  Trends Mol Med       Date:  2017-12-07       Impact factor: 11.951

3.  Descemet Membrane Endothelial Keratoplasty Failure Associated with Innate Immune Activation.

Authors:  Zala Lužnik; Silke Oellerich; Karin Roesch; Jia Yin; Markus Zumbansen; Lars Franken; Gerrit R J Melles; Reza Dana
Journal:  Ophthalmology       Date:  2019-04-12       Impact factor: 12.079

4.  Two case reports of continued progression of chronic ocular graft-versus-host disease without concurrent systemic comorbidities treated by amniotic membrane transplantation.

Authors:  Hideto Ikarashi; Naohiko Aketa; Eisuke Shimizu; Yoji Takano; Tetsuya Kawakita; Yuichi Uchino; Yukihiro Matsumoto; Junko Ogawa; Kazuo Tsubota; Yoko Ogawa
Journal:  BMC Ophthalmol       Date:  2021-04-07       Impact factor: 2.209

5.  The role of IL-6-174 G/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis.

Authors:  Zulvikar Syambani Ulhaq; Gita Vita Soraya; Lely Retno Wulandari
Journal:  Sci Rep       Date:  2020-10-15       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.